JP2025511135A - Ｎｒｐ１結合ドメインを含む二重特異性抗体およびその使用方法 - Google Patents

Ｎｒｐ１結合ドメインを含む二重特異性抗体およびその使用方法 Download PDF

Info

Publication number
JP2025511135A
JP2025511135A JP2024557935A JP2024557935A JP2025511135A JP 2025511135 A JP2025511135 A JP 2025511135A JP 2024557935 A JP2024557935 A JP 2024557935A JP 2024557935 A JP2024557935 A JP 2024557935A JP 2025511135 A JP2025511135 A JP 2025511135A
Authority
JP
Japan
Prior art keywords
seq
bispecific antibody
binding
nrp1
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511135A5 (https=
Inventor
ソン，ホジュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pinetree Therapeutics Inc
Original Assignee
Pinetree Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pinetree Therapeutics Inc filed Critical Pinetree Therapeutics Inc
Publication of JP2025511135A publication Critical patent/JP2025511135A/ja
Publication of JP2025511135A5 publication Critical patent/JP2025511135A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2024557935A 2022-03-30 2023-03-30 Ｎｒｐ１結合ドメインを含む二重特異性抗体およびその使用方法 Pending JP2025511135A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263325312P 2022-03-30 2022-03-30
US202263325317P 2022-03-30 2022-03-30
US63/325,312 2022-03-30
US63/325,317 2022-03-30
PCT/US2023/016963 WO2023192514A1 (en) 2022-03-30 2023-03-30 Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025511135A true JP2025511135A (ja) 2025-04-15
JP2025511135A5 JP2025511135A5 (https=) 2025-11-04

Family

ID=86184900

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024557935A Pending JP2025511135A (ja) 2022-03-30 2023-03-30 Ｎｒｐ１結合ドメインを含む二重特異性抗体およびその使用方法

Country Status (13)

Country Link
US (1) US20240101682A1 (https=)
EP (1) EP4499696A1 (https=)
JP (1) JP2025511135A (https=)
KR (1) KR20240163751A (https=)
CN (1) CN119403831A (https=)
AU (1) AU2023245728A1 (https=)
CA (1) CA3255754A1 (https=)
CL (1) CL2024002899A1 (https=)
CO (1) CO2024014799A2 (https=)
CR (1) CR20240462A (https=)
IL (1) IL315960A (https=)
MX (1) MX2024011978A (https=)
WO (1) WO2023192514A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318499A (en) * 2022-07-30 2025-03-01 Pinetree Therapeutics Inc Compounds for targeted lysosomal degradation and methods of using them
AU2023378712A1 (en) * 2022-11-07 2025-05-01 Pinetree Therapeutics, Inc. Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009514972A (ja) * 2005-11-08 2009-04-09 ジェネンテック・インコーポレーテッド ニューロピリンアンタゴニスト
US20190062375A1 (en) * 2016-03-29 2019-02-28 Ajou University Industry-Academic Cooperation Foun Dation Composition for overcoming resistance to egfr-targeting agent
WO2020027224A1 (ja) * 2018-07-31 2020-02-06 国立大学法人東京大学 新たな結合特異性を抗体に付与する超汎用法
WO2020079280A1 (en) * 2018-10-19 2020-04-23 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of squamous cell cancers
JP2020517659A (ja) * 2017-04-24 2020-06-18 イクノス サイエンシズ エスエー Ｅｇｆｒ陽性癌の治療のためのｔ細胞リダイレクト二重特異性抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017171373A2 (ko) * 2016-03-29 2017-10-05 아주대학교산학협력단 Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009514972A (ja) * 2005-11-08 2009-04-09 ジェネンテック・インコーポレーテッド ニューロピリンアンタゴニスト
US20190062375A1 (en) * 2016-03-29 2019-02-28 Ajou University Industry-Academic Cooperation Foun Dation Composition for overcoming resistance to egfr-targeting agent
JP2020517659A (ja) * 2017-04-24 2020-06-18 イクノス サイエンシズ エスエー Ｅｇｆｒ陽性癌の治療のためのｔ細胞リダイレクト二重特異性抗体
WO2020027224A1 (ja) * 2018-07-31 2020-02-06 国立大学法人東京大学 新たな結合特異性を抗体に付与する超汎用法
WO2020079280A1 (en) * 2018-10-19 2020-04-23 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of squamous cell cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANCER LETTERS, vol. 466, JPN6025046819, 2019, pages 23 - 34, ISSN: 0005733796 *

Also Published As

Publication number Publication date
KR20240163751A (ko) 2024-11-19
CL2024002899A1 (es) 2025-02-07
US20240101682A1 (en) 2024-03-28
CA3255754A1 (en) 2023-10-05
EP4499696A1 (en) 2025-02-05
AU2023245728A1 (en) 2024-09-26
WO2023192514A1 (en) 2023-10-05
CO2024014799A2 (es) 2024-11-18
IL315960A (en) 2024-11-01
CN119403831A (zh) 2025-02-07
CR20240462A (es) 2024-12-11
MX2024011978A (es) 2025-02-10

Similar Documents

Publication Publication Date Title
US11203640B2 (en) Checkpoint inhibitor bispecific antibodies
US20180009892A1 (en) Anti-ror1 antibodies
US20230203202A1 (en) Proteins binding nkg2d, cd16 and 5t4
JP2020511993A (ja) ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ−２及びＥｒｂＢ３結合二重特異性抗体
CN117730096A (zh) 结合nkg2d、cd16和egfr的蛋白质
AU2022206035B2 (en) Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
US20240101682A1 (en) Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
CN110636861A (zh) 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法
KR20240082379A (ko) 암 치료 방법 및 이의 약제학적 조성물
US20250215087A1 (en) Combination therapy of kras inhibitor and treg depleting agent
KR20250044738A (ko) 표적화 라이소좀 분해를 위한 조성물 및 이의 사용 방법
JP7850365B2 (ja) Ｌｇｒ５及びｅｇｆｒに結合する抗体によるがんの治療
EA052797B1 (ru) Биспецифичные антитела, содержащие домен, связывающий nrp1, и способы их применения
TW201642904A (zh) 含抗ｆｇｆｒ２抗體及其他藥劑之組成物
JP7854948B2 (ja) Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法
KR20260051054A (ko) 표적화 라이소좀 분해를 위한 비-수용체 티로신 키나제 조성물 및 이의 이용 방법
TW202434631A (zh) 抗il-2抗體之使用方法
TW202436339A (zh) 治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
KR20240108799A (ko) 항 엽산 수용체 접합체 암 요법
HK40019947A (en) Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
CA2957531A1 (en) Sirp alpha-antibody fusion proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251023

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260216

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260414